Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-101 in Diabetic Lower Leg and Foot Ulcers
NCT03888053Phase 1Completed
- Sponsor
- Blue Blood Biotech Corp.
- Start
- Mar 2018
- Primary completion
- Dec 2021
- Modality
- Gene Editing, Gene Silencing, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing BB-101 Treatment Arm with Placebo Arm (2 arms). Primary endpoints: Incidence and severity of local reactions at 6 weeks, Incidence and severity of adverse events at 6 weeks and 6 more. Started Mar 2018; status: completed.
02
Drugs
Prunbomodulin
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT03888053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888053.